Paul
03-30-2004, 11:55 PM
CP-724 714 an oral HER2 receptor inhibitor was discovered as part of OSI's long-standing cancer discovery program with Pfizer Inc. and is currently in Phase I clinical development by Pfizer. Data presented at the meeting demonstrated that CP-724 714 has significant anti-proliferative activity in human breast cancer cell lines with elevated levels of HER2 (9 of 9 cell lines) whereas cell lines without HER2 amplification demonstrated activity in fewer cell lines (3 of 13 cell lines).
Additional data reported by OSI at the AACR annual meeting suggested that the combination of CP-724 714 and Herceptin(R) provided better anti-tumor efficacy than treatment by either agent alone in a human breast carcinoma xenograft model.
Additional data reported by OSI at the AACR annual meeting suggested that the combination of CP-724 714 and Herceptin(R) provided better anti-tumor efficacy than treatment by either agent alone in a human breast carcinoma xenograft model.